clonoSEQ ensures consistent, comparable and reproducible results regardless of the treatment facility or testing timepoint, providing insights to guide next steps in treatment. clonoSEQ is FDA-cleared to assess MRD in CLL, MM, and ALL. For further info: https://rb.gy/8tju9y
clonoSEQ
Medical and Diagnostic Laboratories
Seattle, Washington 376 followers
clonoSEQ® detects and tracks measurable residual disease (MRD) in lymphoid cancers to help inform patient care.
About us
Hundreds of academic and community centers use clonoSEQ® to track measurable residual disease (MRD). Why? Because with advanced treatments driving better outcomes, clonoSEQ has the sensitivity to deeply monitor those outcomes and inform patients’ next steps.1-5 Our customers choose to measure and monitor MRD with clonoSEQ because: • clonoSEQ is the most sensitive measure of MRD currently available2 • clonoSEQ is FDA-cleared and CLIA-validated* • clonoSEQ has national Medicare coverage† *clonoSEQ MRD test is FDA-cleared for B-ALL, CLL, and MM. clonoSEQ MRD test is CLIA-validated for DLBCL. †Medicare Advantage patients may have out-of-pocket costs for their unmet deductible or copays. Learn more about clonoSEQ by visiting https://www.clonoseq.com/about/. 1. Data on file. Adaptive Biotechnologies. 2022. 2. clonoSEQ®. [technical summary]. Seattle, WA: Adaptive Biotechnologies; 2020. 3. Lahuerta J, et al. J Clin Oncol. 2017;35(25):2900-2910. 4. Short N, et al. Am J Hematol. 2019;94:257-265. 5. Thompson P, et al. Leukemia. 2018;32(11):2388-2398.
- Website
-
https://www.clonoseq.com/
External link for clonoSEQ
- Industry
- Medical and Diagnostic Laboratories
- Company size
- 501-1,000 employees
- Headquarters
- Seattle, Washington
Updates
-
clonoSEQ MRD testing can precisely identify, quantify & track a patient’s dominant cancer sequences over time to provide insights for personalized treatment. clonoSEQ is FDA-cleared to assess MRD in CLL, MM and ALL. For further info: https://rb.gy/8tju9y
-
The deep sensitivity of clonoSEQ MRD testing detects subtle changes in disease burden, allowing you and your team to make timely adjustments in treatment. clonoSEQ is FDA-cleared to assess MRD in CLL, MM, and ALL. For further info: https://rb.gy/8tju9y
-
clonoSEQ MRD testing is highly sensitive, specific to your cancer, and comparable across time. It offers detailed insights so you and your doctor can feel confident in your treatment plan. clonoSEQ is FDA-cleared to assess MRD in CLL, MM, and ALL. For further info: https://rb.gy/8tju9y
-
Blood cancers require comprehensive approaches. clonoSEQ MRD testing complements other tools with more frequent, patient-specific insights to keep a pulse on disease burden. clonoSEQ is FDA-cleared to assess MRD in CLL, MM, and ALL. For further info: https://rb.gy/8tju9y
-
Using MRD as a primary endpoint in accelerated approval clinical trials for multiple myeloma has great potential to provide patients with access to new and novel therapies faster than ever before! https://lnkd.in/g4ZpEps7
-
Monitor disease burden with confidence. clonoSEQ MRD testing can be integrated into routine blood work to allow for more frequent monitoring and earlier detection of changes. clonoSEQ is FDA-cleared to assess MRD in CLL, MM, and ALL. For further info: https://rb.gy/8tju9y
-
Personalize patient care across the treatment continuum. clonoSEQ MRD testing informs changes in therapy based on subtle but meaningful changes in disease burden. clonoSEQ is FDA-cleared to assess MRD in CLL, MM, and ALL. For further info: https://rb.gy/8tju9y
-
Catch disease resurgence early with frequent MRD assessment. clonoSEQ detects disease burden with deep sensitivity, keeping you and your patient a step ahead of relapse. clonoSEQ is FDA-cleared to assess MRD in CLL, MM, and ALL. For further info: https://rb.gy/8tju9y
-
Sensitivity matters when evaluating the efficacy of newer therapies. clonoSEQ MRD testing deeply assesses individual responses, providing pivotal insights for personalized care. clonoSEQ is FDA-cleared to assess MRD in CLL, MM, and ALL. For further info: https://rb.gy/8tju9y